Carfilzomib (PR-171) is a second-generation, irreversible proteasome inhibitor targeting the β5 subunit (IC50 = 5.2 nM) and β5i subunit (IC50 = 14 nM), inducing apoptosis in multiple myeloma and other cancers. Reagent grade, for research purpose.
Usually ships within 24 hours.